LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

LLY

1,078.2

+1.07%↑

JNJ

230.54

-1.72%↓

ABBV

213

-1.44%↓

UNH

377.51

-2.75%↓

AZN

187.71

+0.25%↑

Strona główna・Stock List・Guardant Health Inc

Guardant Health Inc

Open

SectorHealthcare

119.85 1.28

Buy Sell

Overview

Share price change

24h

Current

Min

114.61

Max

120.19

Key metrics
By Trading Economics
Income	16M -112M
Sales	20M 302M
EPS	-0.45
Profit margin	-37.152
Employees	2,490
EBITDA	18M -101M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+7.95% upside

Dividends
By Dow Jones
Next Earnings	29 lip 2026

Market Stats
By TradingEconomics
Market Cap	598M 13B
Previous open	118.57
Previous close	119.85

News Sentiment

By Acuity

100%

326 / 345 Ranking in Healthcare

Guardant Health Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 maj 2026, 08:24 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 maj 2026, 21:22 UTC

Earnings

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 maj 2026, 20:50 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 maj 2026, 16:20 UTC

Market Talk

Earnings

Basic Materials Roundup: Market Talk

25 maj 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 maj 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 maj 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 maj 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 maj 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 maj 2026, 12:56 UTC

Market Talk

Earnings

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 maj 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 maj 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25 maj 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 maj 2026, 12:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Delivery Hero's Assets Look Strategic -- Market Talk

25 maj 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 maj 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 maj 2026, 10:05 UTC

Earnings

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 maj 2026, 10:04 UTC

Earnings

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 maj 2026, 10:03 UTC

Earnings

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 maj 2026, 10:02 UTC

Earnings

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 maj 2026, 10:01 UTC

Earnings

Tenaga Nasional 1Q Net Up 3.7% on Year

25 maj 2026, 10:00 UTC

Earnings

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q EPS MYR0.1883

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Rev MYR17.1B

25 maj 2026, 09:56 UTC

Earnings

Tenaga Nasional 1Q Net MYR1.1B

25 maj 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 maj 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25 maj 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 maj 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer Comparison

Price change

Guardant Health Inc Forecast

Price Target

By TipRanks

7.95% upside

12 Months Forecast

Average 128.41 USD 7.95%

High 150 USD

Low 95 USD

Based on 15 Wall Street analysts offering 12 month price targets forGuardant Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to Guardant Health Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.